Full Press Release Details
National Stock Exchange of India Ltd. (Stock Code: DRREDDY-EQ)
BSE Limited (Stock Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)
Sub: Intimation of Earnings call
Please find enclosed a notification titled "Dr.
Reddy's to release Q1FY25 results on Saturday, July 27th, 2024, Earnings call slated for Saturday, July 27th @4:30 PM IST / 7:00 AM ET."
This is for your information and records.
For Dr. Reddy's Laboratories Limited
Company Secretary, Compliance Officer & Head-CSR
| CONTACT | ||
| DR. REDDY'S LABORATORIES LTD. | Investor relationS | Media relationS |
| 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034, Telangana, India. | RICHA PERIWAL richaperiwal@drreddys.com AISHWARYA SITHARAM aishwaryasitharam@drreddys.com | USHA IYER ushaiyer@drreddys.com |
Dr. Reddy's to release Q1FY25 results on Saturday,
Earnings call slated for Saturday, July 27th @4:30
Hyderabad, India, July 10th, 2024
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY,
NYSE: RDY, NSEIFSC: DRREDDY) will announce results for the quarter ended June 30th, 2024 on Saturday, July 27th,
2024 after the Board Meeting.
| Event | Date and Time | Medium |
| Release of financial results | July 27 th , 2024, after the Board Meeting | Stock Exchange, Media, Company Website, Email |
| Press Meet Presentation | Will be available on the Company's Website | Company's Website www.drreddys.com |
| Earnings Call | July 27 th , 4:30 PM IST / 7:00 AM ET | Hosted by the Company (Details below) |
| Playback of Earnings Call | After the earnings call till August 3 rd , 2024 | Details below |
| Audio as well as Transcript of the Earnings call | Will be available on the Company's Website | Company's Website www.drreddys.com |
Following the release, the management of the Company
will host Its earnings call to discuss the Company's financial performance. (Dial-in and other details given below)
The play back will be available after the earnings
call, till August 3rd, 2024.
For play back dial in phone No: +91 22 7194 5757,
and Playback Code is 57537.
Conference Joining Information
Option 1: Express Join with DiamondPass
Pre-register with the below link and join without
waiting for the operator.
linkSecurityString=3f1c80877a
Option 2: Join through below Dial-In
| Universal Access Number: | +91 22 6280 1219 |
| +91 22 7115 8120 | |
| International Toll Free Number: | USA: 1 866 746 2133 |
| UK: 0 808 101 1573 | |
| Singapore: 800 101 2045 | |
| Hong Kong: 800 964 448 |
No password/pin number is necessary to dial in to
any of the above numbers. The operator will provide instructions on asking questions before and during the call.
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:
RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to
providing access to affordable and innovative medicines. Driven by our purpose of Good
we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas
of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include -
USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several
industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions,
we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access
and affordability for patients; diversity; and governance. For more information, log on to:www.drreddys.com.
Disclaimer: This press release may include
statements of future expectations and other forward-looking statements that are based on the management's
current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events
to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason
of context, the words "may", "will", "should", "expects", "plans", "intends",
"anticipates", "believes", "estimates", "predicts", "potential", or "continue"
and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in
such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults ,
currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity
levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the
policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues,
and (vi) the susceptibility of our industry and the markets addressed by our, and our customers',
products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including
coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission,
including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on
Form 20-F for the year ended March 31, 2024. The company assumes no obligation to update any information contained herein."
The company assumes no obligation to update any information contained herein.